Every 8-K that Immix Biopharma Inc (IMMX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMMX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMMX filings page.
Immix Biopharma, Inc. reported that as of July 17, 2026, Richard Graydon has been terminated and is no longer with the company. The company states that the departure is for reasons unrelated to his activities at Immix Biopharma.
Given his short tenure, management believes this change has no material effect on the business.
Immix Biopharma, Inc. reported the final voting results from its 2026 Annual Meeting of stockholders held on May 22, 2026. Stockholders elected all listed director nominees, including Ilya Rachman, Gabriel Morris and others, with each receiving over 34 million votes in favor and relatively few votes withheld.
Each director election also recorded 6,445,683 or 6,445,684 broker non-votes. A second proposal was approved with 42,276,496 votes for, 11,526 against and 18,442 abstentions, indicating strong support from voting shareholders for the matters presented.
Immix Biopharma, Inc. is raising capital through an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share, for expected gross proceeds of $150 million and estimated net proceeds of about $140.65 million. The deal is being led by Morgan Stanley under an existing shelf registration statement and is expected to close around May 22, 2026, subject to customary conditions. Immix plans to use the cash mainly to fund development of its BCMA-targeted CAR-T therapy NXC-201, as well as for working capital and general corporate purposes, and believes this financing, together with existing cash, will fund operations into mid-2028.
Immix Biopharma reported interim Phase 2 NEXICART-2 data showing a 95% complete response (CR) rate, with 19 of the first 20 relapsed/refractory AL amyloidosis patients treated with CAR-T candidate NXC-201 achieving CR.
All minimal residual disease (MRD)-negative patients converted to CR, and all CRs occurred within one year of follow-up, with no relapses observed so far among CR patients. Seventeen of 20 patients showed rapid normalization of diseased light chains, with a median time to initial response of 7 days, and MRD-negativity at 10-5 was reached within 30 days for all MRD-negative patients.
NEXICART-2 is a fully enrolled 45-patient, multi-site U.S. Phase 2 trial with a potentially registrational design, and the next data update is expected in late September 2026. The company also plans a multi-center, randomized Phase 3 trial in newly diagnosed AL amyloidosis patients, targeted to start in the first half of 2027.
Immix Biopharma announced that enrollment is complete in its BLA-enabling NEXICART-2 Phase 2 trial of CAR‑T therapy NXC‑201 for relapsed/refractory AL amyloidosis, a 40‑patient U.S. study. The company expects topline NEXICART‑2 results in Q3 2026, followed by a planned biologics license application submission and potential commercial launch.
NXC‑201 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, and Orphan Drug designations in the U.S., and Orphan status in the EU. Immix also onboarded a commercially experienced Chief Medical Officer with prior leadership roles at Merck and Johnson & Johnson to help prepare for the anticipated regulatory filing.
Immix Biopharma, Inc. entered into Amendment No. 1 to its At The Market Offering Agreement with Citizens JMP Securities, LLC. The amended arrangement allows Immix to sell shares of common stock from time to time in an at-the-market program with an aggregate offering price of up to $100,000,000 under its effective Form S-3 shelf registration.
Citizens JMP Securities will act as sales agent and use commercially reasonable efforts to place shares within company instructions and applicable Nasdaq and regulatory limits. Immix will pay a 3.0% commission on gross sales proceeds and reimburse specified expenses up to $50,000. The filing also includes a legal opinion from Blank Rome LLP on the validity of the shares.
Immix Biopharma, Inc. (IMMX) filed a current report to update the audit firm consents tied to its existing shelf registration. The company obtained new consents dated November 26, 2025 from KMJ Corbin & Company LLP, its former independent registered public accounting firm, and Crowe LLP, its current independent registered public accounting firm. These consents allow the firms’ audit reports dated March 29, 2024 and March 24, 2025 on Immix Biopharma’s consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2024 to be incorporated by reference into the company’s effective Form S-3 registration statement (No. 333-290725) and referenced under the “Experts” section of the related prospectus. The filing does not announce new operating results or business transactions and is primarily an administrative update supporting ongoing use of the existing registration statement.
Immix Biopharma, Inc. filed an 8-K disclosing that on September 5, 2025 it entered into a Securities Purchase Agreement, a Registration Rights Agreement, and issued a form of non-transferable warrant. The filing lists these three exhibits as filed electronically and identifies the report signer as Ilya Rachman, Ph.D., M.D., Chief Executive Officer. No financial terms, purchase amounts, purchaser identities, or timing for registration effectiveness are disclosed in the text provided. The submission indicates these agreements are material events but the document contains only exhibit references, not the underlying pricing, dilution, or use-of-proceeds details.
Immix Biopharma held its 2025 Annual Meeting on June 20, with 72.1% of voting shares represented (20,092,566 shares). Two key proposals were voted upon:
1. Board of Directors Election:
- All eight directors were successfully elected with strong majority support
- Ilya Rachman (CEO), Gabriel Morris, and Jason Hsu received notably high approval rates above 14.3M votes each
- Helen C. Adams and Carey Ng received relatively lower but still substantial support with approximately 13.3-13.6M votes
2. Auditor Appointment:
- Shareholders overwhelmingly approved Crowe LLP as independent auditor for FY2025
- The resolution passed with 19.9M votes in favor (99.3% approval), only 47,622 against, and 98,438 abstentions
The company is classified as an emerging growth company and trades on Nasdaq under symbol IMMX.